Date: 2011-05-04
Type of information: Licensing agreement
Compound: Affibody® molecules and Albumod™ for two targets within the oncology field, HER2 and PDGFR-Beta
Company: Algeta (Norway) Affibody (Sweden)
Therapeutic area: Cancer Oncology
Type agreement: Licensing
Collaboration
Action mechanism:
Disease:
Details: Affibody AB has signed a license and collaboration agreement with Algeta ) with the aim of developing new tumor-targeting alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227. Through the agreement Algeta exclusively licenses Affibody’s two proprietary technology platforms Affibody® molecules and Albumod™ for two targets within the oncology field, HER2 and PDGFR-Beta. Affibody® molecules are a novel class of antibody mimetics that are excellent payload carriers and may in addition have potential efficacy, safety, and administration route benefits. Albumod™ is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life.
Financial terms: The agreement with Algeta includes an upfront payment plus further payments based upon the achievement of certain milestones as well as royalties on sales. Algeta will be responsible for the costs associated with the future development of the products.
Latest news:
